No Data
Lexicon Pharmaceuticals to Announce Topline Results From Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults With Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals Shares Are Trading Higher After the Company Announced Its Lancet Study Met Its Primary Endpoint and Showed Sotagliflozin Reduced Cardiovascular Events in T2D Patients.
Express News | Lexicon Pharmaceuticals Shares Are Trading Higher After the Company Announced Its Lancet Study Met Its Primary Endpoint and Showed Sotagliflozin Reduced Cardiovascular Events in T2D Patients
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Promising Outlook for Lexicon Pharmaceuticals' LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals (LXRX) Gets a Hold From Needham
Unlock the Full List
